Saudi Pharmaceutical Industries & Medical Appliances Corp (SPIMACO) is a vertically integrated generics pharmaceutical manufacturer. The company develops, produces, and distributes high-quality, accessible medicines across a diverse range of therapeutic categories. SPIMACO operates in more than 18 countries and has a strong presence in the MENA region.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

SPIMACO’s R&D strong commitment to innovation and regulatory excellence through its R&D initiatives. The company achieved significant milestones, including the delivery of 36 new product registration files, which encompass super generics, patented non-infringing formulations, and modified-release formulations. It has undertaken significant R&D initiatives, including the successful introduction of Endosa, the first biosimilar fully manufactured end-to-end within the GCC by a national company. In FY2025, SPIMACO transitioned from a Technology Transfer approach to full in-house product development, resulting in the creation of 32 new SKUs, with 24 launched domestically. The company also submitted its first vaccine dossier to the Saudi Food and Drug Authority (SFDA), supporting national vaccine localization priorities. The R&D unit of SPIMACO is responsible for leading product development, acquisition, and registration. It facilitates technology and knowledge transfer, ensures quality control, and addresses quality control (QC) and quality assurance (QA) challenges. The unit also plays a critical role in operational support, resolving key issues for major products and ensuring operational continuity and efficiency. In FY2025, the company spent SAR60.5 million on its R&D activities, which as a percentage of revenue stood at 3.5%.